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ABSTRACT
We have characterized a new locus, BRA3, leading to deregulation of the yeast purine synthesis genes
(ADE genes). We show that bra3 mutations are alleles of the GUK1 gene, which encodes GMP kinase. The
bra3 mutants have a low GMP kinase activity, excrete purines in the medium, and show vegetative growth
defects and resistance to purine base analogs. The bra3 locus also corresponds to the previously described
pur5 locus. Several lines of evidence indicate that the decrease in GMP kinase activity in the bra3 mutants
results in GMP accumulation and feedback inhibition of hypoxanthine-guanine phosphoribosyltransferase
(HGPRT), encoded by the HPT1 gene. First, guk1 and hpt1 mutants share several phenotypes, such as
adenine derepression, purine excretion, and 8-azaguanine resistance. Second, overexpression of HPT1
allows suppression of the deregulated phenotype of the guk1 mutants. Third, we show that purified yeast
HGPRT is inhibited by GMP in vitro. Finally, incorporation of hypoxanthine into nucleotides is similarly
diminished in hpt1 and guk1 mutants in vivo. We conclude that the decrease in GMP kinase activity in
the guk1 mutants results in deregulation of the ADE gene expression by phenocopying a defect in HGPRT.
The possible occurrence of a similar phenomenon in humans is discussed.
MICROORGANISMS modify their metabolism in the repression effect of adenine requires the purinebase to enter the cell, i.e., bra7 mutants are alleles ofresponse to environmental changes. When meta-
bolic precursors are present in the extracellular me- the FCY2 gene that codes for the purine cytosine perme-
ase (see Figure 1; Guetsova et al. 1997). Adenine itselfdium, yeast and bacteria generally use these precursors
instead of synthesizing them de novo. Consequently, the is not the effector molecule since it has to be metabo-
lized into AMP and then ADP to exert its regulatorysynthesis of metabolic enzymes is regulated according
to the presence of metabolites in the medium. effect. There are two possible routes for the synthesis
of AMP from adenine: a direct one catalyzed by adenineSuch a regulatory mechanism exists for the purine
biosynthesis pathway in Saccharomyces cerevisiae. Indeed, phosphoribosyltransferase (APRT) and a more indirect
one requiring four enzymatic steps via the formation ofall the genes encoding enzymes required for de novo
AMP biosynthesis are repressed at the transcriptional hypoxanthine and IMP (see Figure 1). The APRT route
does not seem to play a major role in the repressionlevel by the presence of extracellular purines (adenine
process since disruption of APT1, the APRT encodingor hypoxanthine) (Ma¨ntsa¨la¨ and Zalkin 1984; Giani
gene, had no effect on adenine repression (Guetsovaet al. 1991; Daignan-Fornier and Fink 1992; Denis et
et al. 1997). We found that mutations in the genes en-al. 1998). This regulation process requires two transcrip-
coding hypoxanthine-guanine phosphoribosyltransfer-tion factors, Bas1p and Bas2p (Daignan-Fornier and
ase (HGPRT), adenylosuccinate synthase (Ade12p),Fink 1992), and regulation by extracellular purines has
and adenylosuccinate lyase (Ade13p) abolished the re-been proposed to occur through interactions between
pression signal (BRA6, BRA9, and BRA1 are HPT1,these two factors (Zhang et al. 1997).
ADE12, and ADE13, respectively; Guetsova et al. 1997;To gain an insight into the signal transduction path-
see Figure 1). The major route for the repression signalway between extracellular adenine and the transcription
from adenine to AMP is thus via the formation of hypo-factors, we have isolated mutants in which purine biosyn-
xanthine and IMP. In addition, we have shown thatthesis genes are no longer repressed by extracellular
AMP needs to be phosphorylated into ADP to exert itsadenine (Guetsova et al. 1997). These mutants are
regulatory role (Guetsova et al. 1997).termed bra for bypass of repression by adenine. The
The bra mutants define more than 10 complementa-identification of some of these mutants has shown that
tion groups, indicating that the regulation process is
complex and requires several proteins. To identify a
new partner in the signal transduction pathway, we have
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constructed by insertion of the HindIII-BglII fragment from
the pGUK1 plasmid (Konrad 1992) into a centromeric LEU2
vector named pRS315 (Sikorski and Hieter 1989) linearized
with HindIII and BamHI.
The P1718 plasmid expressing the Hpt1p-His6 fusion in
bacteria was constructed as follows: a 684-bp fragment carrying
the HPT1 coding sequence was amplified by PCR using the
following synthetic oligonucleotides: HPT1Ca, 59-GTGATG
CATATGTCGGCAAACGATAAGC-39 and HPT1Cb, 59-CGAT
GCTCGAGATTGCTTGTGTTCCTGCTC-39. The PCR prod-
uct was cut with NdeI and XhoI and introduced into a pJC20-
HisC expression plasmid linearized with NdeI and XhoI. The
resulting plasmid encodes a 26.7-kD Hpt1p-His6 fusion pro-
tein. The pJC20-HisC vector was generated by introducing a
double-stranded oligonucleotide linker into pJC20 (Konrad
1993) restricted with BamHI and ApaI: 59-GATCC CAT CAC
CAT CAC CAT CAC TGA GGGCC-39 (sense) and 59-C TCA
GTG ATG GTG ATG GTG ATG G-39 (antisense).
LacZ fusions and bGal assays: The lacZ fusions used in this
study have been previously described (Daignan-Fornier and
Fink 1992; Guetsova et al. 1997). P115 is a plasmid carrying
an ADE1-lacZ fusion in a 2m URA3 vector YEp356R (Myers et
al. 1986). P473 is a plasmid carrying an ADE1-lacZ fusion in
a 2m LEU2 vector YEp367 (Myers et al. 1986).
bGal assays were performed as described by Kippert (1995)
on cells grown for 6 hr in the presence or absence of purine
base. bGal units are defined as:
Figure 1.—Scheme of purine interconversion in yeast. The
[OD420 3 1000]/[OD600 3 t(min) 3 vol(ml)] .following abbreviations are used: PRPP, 5-phosphoribosyl-1-
pyrophosphate; IMP, inosine 59-monophosphate; GMP, gua- The repression factor is defined as the ratio of bGal unitsnosine 59-monophosphate; GDP, guanosine 59-diphosphate. measured in the absence of purine to those measured in theGene names are indicated in italic and encode the follow- presence of purine. In each experiment, at least two indepen-ing enzymatic activities: AAH1, adenine deaminase; ADE12, dent bGal assays were performed, and each assay was doneadenylosuccinate synthetase; ADE13, adenylosuccinate lyase; on three independent transformants. The variation betweenADK1, AMP kinase; APT1, adenine phosphoribosyltransferase; assays in each experiment was ,20%.FCY2, purine cytosine permease; GUK1, GMP kinase; HPT1, Integration of LEU2 at the GUK1 locus: A HindIII-XbaI frag-hypoxanthine-guanine phosphoribosyltransferase. The thick ment carrying the GUK1 gene from plasmid P195 was clonedarrows represent the major route for the repression signal by into the pRS305 integrative LEU2 vector (Sikorski andadenine. For the purpose of simplification, nucleosides are Hieter 1989) linearized with HindIII and XbaI. The resultingnot represented. plasmid named P1015 was linearized at the unique StuI site
in the GUK1 coding region and used to transform the Y642
yeast strain. Correct integration of the plasmid at the GUK1
GMP kinase. We document several new phenotypes asso- locus was verified by Southern blot analysis of genomic DNA
extracted from tranformants and cut with BglII (data notciated with the GMP kinase defect and present evidence
shown). One of these transformants named Y882 was used forthat the guk1 mutations result in a phenocopy of hpt1.
linkage analysis.The possible implications for human diseases associated AMP and GMP kinase enzymatic assays: AMP and GMP
with purine overexpression and uric acid excretion are kinase activities in protein extracts were measured using a
discussed. spectrophotometric assay in a coupled lactate dehydrogenase/
pyruvate kinase system according to the method of Agarwal
et al. (1978). Briefly, yeast strains were grown in 20 ml of rich
YPD medium to an OD600 of 0.75 6 0.05. Cells were harvested,MATERIALS AND METHODS
washed with water, and resuspended in 0.6 ml breaking buffer
(20 mm TrisHCl pH 7.9, 10 mm MgCl2, 1 mm EDTA, 5% glyc-Yeast strains and media: Yeast strains are listed in Table 1.
Yeast media were prepared according to Sherman et al. (1986). erol, 1 mm dithiothreitol (DTT), 0.3 m ammonium sulfate,
and 2 mm phenylmethylsulfonyl fluoride). The cells were thenAdenine and hypoxanthine were used at a final concentration
of 0.15 mm. The XGal synthetic medium was prepared using broken with glass beads by vortexing four times for 30 sec in
the cold. After addition of 0.2 ml of breaking buffer, glassthe methods previously described (Dang et al. 1994). The
base analog 8-azaguanine (8AG) was added to the medium at beads and unbroken cells were pelleted in a microfuge for 5
min and 0.5 to 10 ml of the supernatant was used for thea final concentration of 0.2 mg/ml.
Plasmids: pCG3 (Deeley 1992) is a YEp13 (Broach et al. enzymatic assay. The assay was done in 100 mm TrisHCl pH
7.5, 100 mm KCl, 10 mm MgCl2, 0.25 mm NADH, 0.5 mm PEP,1979) derivative carrying the APT1 gene.
P556, the 2m plasmid carrying the HPT1 gene, was obtained 2 mm ATP, 5 units lactate dehydrogenase (Sigma, St. Louis),
and 4 units pyruvate kinase (Sigma) in a final volume of 1by ligating the EcoRI-HindIII fragment from P385 that contains
the HPT1 gene (Guetsova et al. 1997) into the multicopy ml. Finally, 1 mm AMP or GMP was added to the reaction
mix, depending on which nucleotide kinase activity was tested.plasmid YEpLac181 (Gietz and Sugino 1988) linearized with
HindIII and EcoRI. Conversion of AMP to ADP by AMP kinase or that of GMP
to GDP by GMP kinase was monitored by the decrease ofP195, the plasmid carrying the GUK1 wild-type gene, was
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TABLE 1
Yeast strains used in this study
Strain Genotype Source
PLY121a MATa his3-D200 leu2-3,112 lys2-D201 ura3-52 P. Lunjdall
129a MATa his3-D200 leu2-3,112 lys2-D201 ura3-52 bra3-1 (5guk1-1) B. Daignan-Fornier
130a MATa his3-D200 leu2-3,112 lys2-D201 ura3-52 bra3-2 (5guk1-2) B. Daignan-Fornier
PLY122a MATa leu2-3,112 lys2-D201 ura3-52 P. Lunjdall
220a MATa leu2-3,112 lys2-D201 ura3-52 bra3-3 (5guk1-3) B. Daignan-Fornier
239a MATa leu2-3,112 lys2-D201 ura3-52 bra3-4 (5guk1-4) B. Daignan-Fornier
L4364a MATa ade2 his3-D200 leu2-3,112 lys2-D201 ura3-52 G. Fink
Y508a MATa leu2-3,112 lys2-D201 ura3-52 hpt1::URA3 B. Daignan-Fornier
Y642a MATa his3-D200 leu2-3,112 lys2-D201 ura3-52 trp1::hisG B. Daignan-Fornier
Y663a MATa leu2-3,112 lys2-D201 ura3-52 trp1::hisG aah1::URA3 B. Daignan-Fornier
Y882a MATa his3-D200 leu2-3,112 lys2-D201 ura3-52 trp1::hisG GUK1::LEU2-GUK1 This work
Y911a MATa ade2 his3-D200 leu2-3,112 lys2-D201 ura3-52 This work
Y912a MATa his3-D200 leu2-3,112 lys2-D201 ura3-52 guk1-2 This work
Y913a MATa ade2 his3-D200 leu2-3,112 lys2-D201 ura3-52 guk1-2 This work
Y914a MATa his3-D200 leu2-3,112 lys2-D201 ura3-52 This work
Y915a MATa leu2-3,112 lys2-D201 ura3-52 guk1-2 This work
Y916a MATa his3-D200 trp1::hisG leu2-3,112 lys2-D201 ura3-52 aah1::URA3 This work
Y917a MATa his3-D200 trp1::hisG leu2-3,112 lys2-D201 ura3-52 This work
Y918a MATa leu2-3,112 lys2-D201 ura3-52 guk1-2 aah1::URA3 This work
pur5 MATa pur5 R. Woods
Y719 MATa leu2-3,112 ura3-52 pur5 This work
L586 MATa ade1 G. Fink
L587 MATa ade1 G. Fink
a Isogenic strains.
absorbance of NADH at 340 nm (extinction coefficient e 5 xanthine converted into inosine 59-monophosphate. To deter-
mine the Ki value for GMP, the apparent KM (KM app) for hypo-6.2 cm2 mmol21). One unit of enzyme activity is defined as
the consumption of 1 mmol of nucleoside triphosphate per xanthine in the presence of either 50 mm, 100 mm, or 200
minute. Protein concentration was determined using the Bio- mm GMP was assayed. The inhibition was determined to be
Rad (Hercules, CA) Protein Micro Assay system with crystalline competitive since there was no major variation of the yeast
bovine serum albumin serving as the reference standard. GMP HGPRT Vmax when increasing GMP concentration. The Ki was
kinase activity values are the result of two independent enzy- thus calculated using the equation
matic assays, each performed with three different protein ex-
V 5 (Vmax 3 [Hyp])/(KM app 1 [Hyp])tract concentrations.
Yeast HGPRT expression and purification: To produce and
yeast HGPRT, P1718 was expressed in the C41 (DE3) Esche-
richia coli strain (Miroux and Walker 1996). Yeast HGPRT KM app 5 KM (1 1 [GMP]/Ki).
was expressed and purified under native conditions using the
In vivo [14C]hypoxanthine incorporation: Wild-type (Y350),QIAGEN (Chatsworth, CA) QIAexpressionist kit with the fol-
guk1 (220), and hpt1 (Y508) strains were grown in 60 mllowing modifications: in all buffers, NaH2PO4 was replaced by
of minimal medium supplemented with 20 g/liter casaminoTris, and elution buffer contained 350 mm imidazole.
acids, 0.2 mm uracil, and 0.2 mm tryptophan to an OD600 ofDetermination of yeast HGPRT kinetic parameters: HGPRT
1.0. Cells were then harvested and resuspended in 6 ml ofassay was done in a 50-ml mix containing [8-3H]hypoxanthine
the same medium plus 20 mm hypoxanthine containing 1 mCi(20 Ci/mmol, ICN Pharmaceuticals, Irvine, CA), 0.1 mm
[8-14C]hypoxanthine (50 mCi/mmol, ICN). Cells were allowed5-phosphoribosyl-1-pyrophosphate, 100 mm Tris pH 8.0, 4 mm
to grow for 15 or 90 min and then 1 ml of culture was used forDTT, 10 mm MgCl2, and 1.5 ng of purified yeast HGPRT.
extraction of the intracellular purine compounds according toInitial rate measurements were performed at 308 and reactions
Gonzalez et al. (1997). Separation of the purine compoundswere stopped after 90 sec. Hypoxanthine KM value was deter-
was then achieved by HPLC using a supelcosil LC-18 5-mmmined using 1 to 200 mm hypoxanthine concentrations. Each
reversed phase column. Gradient was set up with A bufferreaction was stopped by adding 1 ml PRT stop buffer (50
(0.025 m K2HPO4) and B buffer (0.05 m K2HPO4, 25% metha-mm Na-acetate and 2 mm Na2HPO4 pH 5.0) and lanthanium
nol). The following proportions of A and B buffers, respec-chloride (200 ml of 2.5 m LaCl3), allowing precipitation of the
tively (indicated in parentheses), were used at the indicatednucleotide product. The samples were incubated on ice for
run time: 0 min (98/2), 5 min (96/4), 10 min (70/30), 201 hr and the precipitate was collected on GF/C glass filters,
min (20/80), 24 min (20/80), and 25 min (98/2) and thewashed 6 times with 1.5 ml cold water, and dried at 808 for
flow was 1.25 ml/min. Fractions were collected every 30 sec45 min. The filters were then placed in scintillation counting
during the 5 first min of the run and then every minute. Allvials along with 5 ml Packard Filter Count scintillation liquid
fractions were adjusted with water to 1.25 ml, transferred to(complete LSC-cocktail for counting membrane filters, Pack-
scintillation counting vials along with 5 ml PCS liquid scintil-ard, Meriden, CT) and counted on a TRI CARB 1500 Packard
scintillation counter to determine the amount of [3H]hypo- lation cocktail (Amersham, Buckinghamshire, United King-
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BRA3 is GUK1: The BRA3 gene was cloned by comple-
mentation of the bra3-3 derepression phenotype. This
mutant was transformed with a genomic library carried
on a centromeric vector. Candidates for complementa-
tion were isolated according to their ability to repress
the expression of an ADE1-lacZ fusion in the presence
of adenine. Such candidates were scored as pale blue
among dark blue colonies on XGal medium plus ade-
nine. The P131 plasmid, isolated as complementing the
bra3-3 mutant phenotype, was also shown to comple-
ment the derepression phenotype of the other three
mutants of the complementation group. This plasmid
Figure 2.—Purine excretion by the bra3-1 and bra3-2 mu- was further analyzed and shown to contain a yeast DNA
tants. A lawn of ade1 (L587) cells was plated on purine-free insert that hybridized to chromosome IV (data notSC medium. A suspension of wild-type (PLY121) or bra3 mu-
shown). Sequence analysis of both termini of the yeasttant (129 and 130) cells was dropped onto this lawn. Purine
DNA insert revealed that this plasmid carried a 9.2-kbexcretion was monitored after 5 days at 308.
fragment from chromosome IV. This fragment con-
tained five complete open reading frames (YDR452w
dom), and counted on a TRI CARB 2100TR Packard scintilla- to YDR456w), one of which (YDR454c) corresponded
tion counter to determine the amount of 14C radioactivity in to the previously described GUK1 gene that encodes
each vial. GMP kinase, a purine metabolism enzyme catalyzing
phosphorylation of GMP into GDP (Konrad 1992). Be-
cause of its important role in purine metabolism, weRESULTS
then tested whether the GUK1 gene alone could comple-
The bra3 mutants are resistant to 8-azaguanine and ment the derepression phenotype of bra3-1 and bra3-2
excrete purines: In a previous report, we have shown mutants.
that the bra3 complementation group contains four A centromeric plasmid carrying a 919-bp HindIII-BglII
members, two in each mating type (Guetsova et al. fragment containing only the GUK1 gene was constructed.
1997). All four mutants in addition to their derepression This plasmid and a control plasmid were transformed
phenotype showed resistance to base analogs such as in bra3-1 and bra3-2 mutants carrying an ADE1-lacZ fu-
8-azaadenine (8AA) and 8-azaguanine (8AG). The bra3-2 sion, and the repression by adenine of the ADE1-lacZ
mutant was crossed with a wild-type strain and the mei- fusion expression was tested. The repression factor—
otic products of this cross were scored for adenine re- defined as the ratio between expression of the ADE1-lacZ
pression and 8AG resistance. In 15 analyzed tetrads, fusion under derepression (2ade) and repression (1ade)
we noticed a 2:2 segregation of the colony size on the conditions—was calculated. Results in Table 2 show that
germination plate (data not shown). Interestingly, all whereas the repression factor in bra3-1 and bra3-2 mu-
the spores forming smaller colonies were 8AG resistant tants transformed with the control plasmid was very low
and deregulated for expression of an ADE1-lacZ fusion (1.2 and 1.5, respectively), transformation of the two
(Bra2), while all the large colonies were 8AG sensitive mutants with the plasmid carrying the GUK1 gene re-
and Bra1. Therefore, adenine derepression, resistance
to 8AG, and a growth defect cosegregate in this cross.
The bra3-1 and bra3-2 mutants and the isogenic PLY121 TABLE 2
wild-type strain were grown in rich YPD medium at 308
Expression of an ADE1-LacZ fusion in the wild-typeand their generation time was measured. The bra3-1,
(PLY121) strain and in the bra3-1 (129) and bra3-2bra3-2, and wild-type generation time during exponen- (130) mutants transformed with a CEN plasmid
tial growth was 148, 131, and 109 min, respectively, carrying the GUK1 gene
thus establishing that the bra3 mutants have a slower
vegetative growth. Finally, we found that the bra3-1 and bGal units
Relevantbra3-2 mutants excrete purines in the medium, as shown
genotype pRS315 insert 2Ade 1Ade R.F.aby cross-feeding experiments, using a plate assay based
on the rescue of an ade1 mutant on purine-free medium. Wild type None 161 17 9.5
In this assay, the purine-excreting mutants are sur- Wild type GUK1 145 19 7.6
bra3-1 None 168 142 1.2rounded by a halo of growing ade1 colonies. As shown
bra3-1 GUK1 154 19 8.1in Figure 2, growth of bra3-1 and bra3-2 mutants on a
bra3-2 None 186 125 1.5purine-free medium sustained growth of an adenine
bra3-2 GUK1 183 18 10.2auxotrophic strain. Apparently the bra3-1 mutant was a
a R.F., repression factor.more efficient purine excretor than bra3-2.
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Figure 4.—The pur5 phenotypes are complemented by
GUK1. (A) A lawn of ade1 (L587) cells was plated on purine-
Figure 3.—Complementation of the bra3 mutants’ 8AG free SC medium. The pur5 strain (Y719) transformed with the
resistance by the GUK1 gene. Strains were transformed with indicated plasmids was spotted onto the ade1 lawn. Purine
a control centromeric plasmid or a centromeric plasmid car- excretion was monitored after 4 days at 308. (B) The pur5 strain
rying the wild-type GUK1 gene. A serial dilution of the different (Y719) was transformed with a control centromeric plasmid
transformants was dropped onto SC medium containing 8AG (pRS315) or a centromeric plasmid carrying the wild-type
and the growth on this medium was observed after 3 days at GUK1 gene. A serial dilution of the pur5 transformants was
308. dropped onto SC medium containing 8AG and the growth
on this medium was observed after 3 days at 308.
stored a higher repression factor (8.1 and 10.2, respec-
activity in crude extracts from the bra3-1 and bra3-2tively), similar to the wild-type level (7.6). This experi-
mutants. As expected, GMP kinase activity was found toment thus clearly established that the 919-bp DNA
be severely impaired in the bra3 mutants compared toHindIII-BglII fragment containing the GUK1 gene was
the isogenic wild-type strain (Table 3), while in the samesufficient to restore adenine regulation when intro-
experiment AMP kinase activity used as a control wasduced into the bra3-1 and bra3-2 mutant strains. The
not significantly affected in the bra3 mutants. It is worthGUK1 gene alone was also able to fully complement the
noting that the wild-type AMP and GMP kinase activity8AG resistance of the bra3 mutants (Figure 3).
in the wild-type strain is in good agreement with thoseWe then tested the linkage between the bra3 mutation
previously presented (Konrad 1993).and the GUK1 gene. Since disruption of GUK1 is lethal
From all these data, we conclude that BRA3 is GUK1(Konrad 1992), we could not use a GUK1-disrupted
and therefore renamed the bra3-1, bra3-2, bra3-3, andstrain for linkage analysis. Therefore, we crossed the
bra3-4 alleles guk1-1, guk1-2, guk1-3, and guk1-4, respec-bra3-2 mutant with a wild-type strain in which the LEU2
tively.marker was integrated at the GUK1 locus (Y882, see
On the chromosome IV map, GUK1 is located closematerials and methods). After sporulation of the dip-
to the previously characterized pur5 locus (Mortimerloid, 15 tetrads were dissected. In these tetrads, all the
et al. 1991). This locus was initially described as associ-Leu2 spores were deregulated for expression of an
ated with purine excretion, 8AA and 8AG resistanceADE1-lacZ fusion and were 8AG resistant, while all the
(Armitt and Woods 1970; Woods et al. 1983). To testLeu1 spores were wild type for these phenotypes.
the possibility that GUK1 and PUR5 are the same gene,These results strongly suggested that bra3 mutants are
we transformed the pur5 mutant strain with the wild-alleles of GUK1, the GMP kinase encoding gene. This
type GUK1 gene and found that GUK1 on a centromericwas further demonstrated by measuring GMP kinase
plasmid complemented the purine excretion (Figure
4A) and the 8AG-resistance phenotype of pur5 (Figure
TABLE 3 4B). Consistently, the pur5 and guk1-2 mutants did not
complement for purine excretion and 8AG resistanceAMP and GMP kinase activity in crude extracts
(data not shown). Finally, we crossed the pur5 mutantfrom the wild-type (PLY121) strain and the
bra3-1 (129) and bra3-2 (130) mutants with the Y882 strain in which the LEU2 marker is inte-
grated at the GUK1 locus. After sporulation of the dip-
Specific activity (units/mg protein) loid, 17 tetrads were dissected. In these tetrads, all the
Relevant
Leu2 spores were 8AG resistant, while the Leu1 sporesgenotype AMP kinasea GMP kinasea
were 8AG sensitive (data not shown). Altogether these
Wild type 2.227 6 0.270 0.369 6 0.066 data show that pur5 is an allele of the GUK1 gene.
bra3-1 2.335 6 0.445 0.018 6 0.009 Utilization of adenine through the APRT route by-
bra3-2 3.052 6 0.755 0.032 6 0.018 passes the deregulation phenotype of the guk1 mutants:
a Average 6 standard deviation. Why should a mutation in the GUK1 gene induce a
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TABLE 4
Bypass of ADE1-LacZ derepression in guk1 mutants (A) by overexpression of APT1
or (B) by combining the guk1 mutation with an aah1 mutation
bGal units
Relevant
Strain genotype Multicopy plasmid 0a 1 Adea 1 Hypa
A.
PLY121 Wild type YEp13 210 44 57
PLY121 Wild type APT1 in YEp13 225 36 75
130 guk1-2 YEp13 253 142 281
130 guk1-2 APT1 in YEp13 240 64 211
B.
Y917 Wild type — 448 97 118
Y915 guk1-2 — 337 235 355
Y916 aah1 — 413 98 99
Y918 aah1 guk1-2 — 317 88 310
a 0, 1Ade, and 1Hyp stand for no purine base, adenine, and hypoxanthine added to the growth medium,
respectively.
deregulation of ADE gene expression in response to derepression phenotype in the guk1 mutants. We tested
this prediction by crossing an aah1::URA3 disruptedadenine? We have previously shown (Guetsova et al.
1997) that adenine needs to be metabolized into ADP strain (Y663) with the guk1-2 mutant. Several tetrads
were dissected from this cross and tetratypes carryingto exert its regulatory role (see Introduction and Figure
1). Furthermore, the production of ADP from adenine the four combinations of these two mutations were
transformed with an ADE1-lacZ fusion to allow evalua-preferentially occurs through the HPRT route (forma-
tion of hypoxanthine, IMP, and then AMP) rather than tion of the repression by adenine. Results presented in
Table 4B show that both adenine and hypoxanthinedirectly via APRT (see the Introduction section and
Guetsova et al. 1997). We reasoned that if one of the efficiently repressed expression of the fusion in the
wild-type and aah1 spores. As expected, adenine andreactions required for AMP synthesis from adenine is
affected in the guk1 mutants, overexpression of the hypoxanthine, respectively, had little or no effect on ex-
pression of the ADE1-lacZ reporter gene in the guk1-2APT1 gene (encoding APRT) should suppress the ade-
nine deregulation in these mutants. Indeed, the direct mutant. Finally, in the aah1 guk1-2 double mutant, ade-
nine but not hypoxanthine repressed expression of thetransformation of adenine into AMP should bypass the
HPRT route (see Figure 1). Such a bypass was previously reporter fusion. Therefore, repression by adenine is
effective in the double mutant because adenine can beshown for a hpt1 mutant (Guetsova et al. 1997). Results
in Table 4A show that overexpression of APT1 increased metabolized directly into AMP, whereas hypoxanthine,
which must be transformed into AMP via the HPRTthe regulation factor by adenine from 1.8 to 3.8 in the
guk1-2 strain. As an internal control, overexpression of route, cannot repress the ADE genes. We conclude that
the guk1-2 mutation most probably affects the pathwayAPT1 had no effect on regulation by hypoxanthine, a
purine base that cannot be utilized through the APRT between hypoxanthine and AMP.
guk1 mutations phenocopy a HGPRT defect: In theroute (see Figure 1). This result suggests that the guk1
mutation affects adenine regulation via the HPRT route guk1 mutants, the severe decrease in GMP kinase activity
could lead to GMP accumulation, which could in turn(Aah1p, Hpt1p, Ade12p, Ade13p). Consistently, in the
guk1 mutant transformed with the control plasmid, hy- inhibit activity of HGPRT, a key enzyme in the adenine
repression process (HPT1 is BRA6, Guetsova et al.poxanthine cannot repress ADE1-lacZ expression at all,
while adenine has a weak repression effect. 1997). Indeed, guk1 and hpt1 mutants share several phe-
notypes (adenine derepression, purine excretion, andThis hypothesis was further tested in an independent
approach using an aah1 mutant. The AAH1 gene, en- 8-azaguanine resistance).
This hypothesis was tested by monitoring the effectcoding adenine deaminase, participates in the transfor-
mation of adenine into AMP through the HPRT route of overexpression of HPT1 on adenine regulation in
the guk1 mutants. Results (Figure 5A) show that overex-but an aah1 mutant is not deregulated. We hypothesized
that in such a mutant, more adenine is available for pression of HPT1 suppressed the deregulated pheno-
type of the guk1 mutants. Consistently, overexpressionApt1p, which transforms it directly into AMP (Guet-
sova et al. 1997; see Figure 1). Thus, if the guk1 mutation of HPT1 allowed suppression of the purine excretion
phenotype of a guk1 mutant (Figure 5B). The guk1 muta-has an effect on AMP synthesis via Hpt1p, Ade12p, or
Ade13p, an aah1 mutation should suppress the adenine tion thus seems to affect Hpt1p activity and a simple
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Figure 5.—HPT1 overexpression suppresses the pur5 phe- Figure 6.—Yeast HGPRT is feedback inhibited by GMP. A
notypes. (A) Expression of an ADE1-lacZ fusion was monitored Hpt1p-His6 fusion protein was purified from E. coli and assayedby measuring bGal activity in the wild-type and guk1-2 strains for hypoxanthine phosphoribosyltransferase activity. The KMtransformed with a control multicopy plasmid (YEpLac181) and KM app for hypoxanthine were determined in the absenceor a 2m plasmid overexpressing HPT1 (P556). Transformed of GMP and in the presence of either 50, 100, or 200 mm
strains were grown for 6 hr in the presence or absence of GMP. The Ki for GMP was then calculated as described inadenine as indicated. (B) A lawn of ade1 (L586) cells was materials and methods.
plated onto purine-free SC medium. The pur5 strain (Y719),
transformed with either a control plasmid (YEpLac181) or a
plasmid overexpressing HPT1 (P556), was spotted onto the cleotides in vivo. Results presented in Figure 7B showade1 lawn. Purine excretion was monitored after 4 days at 308.
that guk1-3 and hpt1 mutants accumulated radiolabeled
hypoxanthine. Both mutants had difficulty converting
hypoxanthine into nucleotides while the isogenic wild-explanation would be that HGPRT activity could show
feedback inhibition by GMP accumulated in the guk1 type strain did not. As expected, this conversion ap-
peared less affected in the partially inactive guk1-3 mu-mutants.
Feedback inhibition of HGPRT by GMP was assayed tant than in the hpt1 knock-out. We conclude that the
guk1 mutations characterized in this report result in ain vitro on a Hpt1p-His6 protein. Hpt1p-His6 was ex-
pressed and purified from E. coli and we then deter- phenocopy of a HGPRT defect.
mined its kinetic parameters. The KM for hypoxanthine
was 17 mm, the kcat was 5.2 sec21, and the estimated Ki for DISCUSSION
GMP was 26 mm (Figure 6). Therefore, GMP feedback
inhibits the yeast HGPRT, further suggesting that guk1 Consequences of a GMP kinase defect in yeast: Mu-
tants of the bra3 complementation group were initiallymutations could phenocopy a HGPRT defect. This was
confirmed by assaying in vivo whether hypoxanthine isolated for their ability to derepress the purine de novo
pathway genes (Guetsova et al. 1997). Complementa-utilization was affected in the guk1 mutants.
First, we tested whether a double ade2 guk1 mutant tion and linkage data identified BRA3 as GUK1, the
GMP kinase gene. Here, we show that pur5, a previouslywould behave like an ade2 hpt1 mutant, i.e., grow on
medium supplemented with adenine but not hypoxan- described purine excretion mutant (Armitt and
Woods 1970), is also allelic to GUK1. Mutations at thethine (Guetsova et al. 1997). The guk1-2 mutant was
crossed with an ade2 isogenic strain (L4364). After spor- guk1 locus lead to multiple phenotypes. Some of these
are likely to be due to the impaired GDP synthesisulation of the diploid, the tetrads were dissected. Among
these, a tetratype was characterized by monitoring the whereas others are more probably due to the decrease
in HGPRT activity resulting from GMP accumulation.ade2 mutation with adenine auxotrophy and the guk1
mutation with 8AG resistance. Results (Figure 7A) show For example, the growth defect of the guk1 mutants
most probably results from the GDP starvation sincethat a double ade2 guk1-2 mutant could not utilize hypo-
xanthine as a purine source and that it required extra- GUK1 is an essential gene (Konrad 1992), while knock-
out of HPT1 does not lead to any vegetative growthcellular adenine for growth. This result confirms that a
double ade2 guk1-2 mutant has properties similar to an defect (Guetsova et al. 1997). On the other hand, the
purine excretion and deregulation phenotypes areade2 hpt1 strain.
Second, we directly assayed whether a guk1 mutant likely to be due to the HGPRT defect phenocopy since
both phenotypes have been reported for hpt1 mutantscould incorporate radiolabeled hypoxanthine into nu-
960 K. Lecoq, M. Konrad and B. Daignan-Fornier
(Woods et al. 1983; Guetsova et al. 1997) and are sup- mutation complemented by GUK1 was recently shown
to have a defect in glycosylation, most probably becausepressed by overexpression of HPT1 (this work). We have
of a lack in GDP-mannose (Shimma et al. 1998). Wefound (K. Lecoq and B. Daignan-Fornier, unpub-
have found that our mutants mate and sporulate nor-lished results) that the pur5 mutants excrete a mix of
mally (data not shown) even under conditions wherehypoxanthine, guanine, xanthine, inosine, and guano-
GDP is starting to be limiting for vegetative growth.sine. Resistance of the pur5 mutant to 8AA but not
guk1: a hpt1 phenocopy that leads to ADE gene de-8AG was previously shown to be abolished when purine
repression and purine excretion: In this report, we showexcretion is suppressed by the su-pur mutation (Lomax
that mutations in the GUK1 gene cause ADE gene dere-and Woods 1973). This is interpreted as follows: ex-
pression and purine excretion. We present several linescreted purines compete with 8AA for uptake and lead
of evidence suggesting that the guk1 mutations affectto an apparent resistance due to inefficient uptake of
HGPRT, a key enzyme whose lack causes ADE genethe analog. In contrast, 8AG resistance is likely to be
derepression and purine excretion (Guetsova et al.due to the GMP kinase defect or to the HGPRT pheno-
1997). We propose that guk1 phenocopies hpt1 as acopy that would impair transformation of 8AG into its
result of HGPRT feedback inhibition by GMP, which istoxic form.
likely to accumulate in the GMP kinase-deficient mu-Because guanine nucleotides are involved in multiple
tants. Such a feedback inhibition is documented in thiscellular processes, it is not surprising that GMP kinase
report and has already been reported for humanmutants show a variety of phenotypes. Our guk1 mutants
HGPRT (Henderson et al. 1968).could thus prove to be a useful tool to study the effect
Could a defect in human GMP kinase lead to purineof GDP and GTP starvation in yeast. Interestingly, a
overproduction and excretion as it does in yeast? It is
well known that pathological purine overproduction
and excretion lead to accumulation of extracellular hy-
poxanthine. This, in turn, is converted into uric acid,
an insoluble compound that accumulates in joints and
causes hyperuricemia and gout. A HGPRT defect in
humans induces purine overproduction and excretion
(Kelley et al. 1969) as it does in yeast (Woods et al.
1983; Guetsova et al. 1997). The finding that a defect
in GMP kinase phenocopies a HGPRT defect may there-
fore have implications for human diseases. It is tempting
to assume that a defect in human GMP kinase might
be the primary cause of, or at least be implicated in,
some cases of hyperuricemia. This assumption may have
important consequences since all causes of hereditary
gout are not yet identified and only two human genes
encoding HGPRT and PRPP synthetase have been
Figure 7.—In vivo hypoxanthine utilization is affected in
the guk1-2 mutant. (A) Growth of an ade2 guk1-2 double mu-
tant on various purine sources. The different strains were
transformed with a CEN plasmid containing no insert
(pRS315), the ADE2 gene (pASZ11, Stotz and Linder 1990),
or the GUK1 gene (P195). Transformants were grown on SC
medium or on the same medium supplemented with 8AG,
adenine (Ade), or hypoxanthine (Hyp). Growth was moni-
tored after 3 days. (B) [14C]Hypoxanthine accumulation in
the hpt1 and guk1 mutants. Isogenic strains that were either
wild type (Y350, A), guk1-3 (220, B), or hpt1 (Y508, C) were
first grown in minimal medium and then transferred into the
same medium containing [14C]hypoxanthine for either 15 min
(left) or 90 min (right). Purine derivatives were extracted and
separated by HPLC and each fraction was counted as described
in materials and methods. Radioactivity detected in the
fractions (expressed in disintegrations per minute) is pre-
sented as a function of retention time on the column. Arrows
indicate the identified peaks with the following abbreviations:
Ade, adenine; Hyp, hypoxanthine; Ino, inosine; NT, mix of
all purine nucleotides (mono-, di-, and triphosphate).
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